What development phase is SYNTHETIC CONJUGATED ESTROGENS, B in?

SYNTHETIC CONJUGATED ESTROGENS, B is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

SYNTHETIC CONJUGATED ESTROGENS, B

FDA-approved approved Quality 1/100

At a glance

Generic name	SYNTHETIC CONJUGATED ESTROGENS, B
Phase	FDA-approved
First approval	2004

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy (PHASE3)
Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SYNTHETIC CONJUGATED ESTROGENS, B CI brief — competitive landscape report
SYNTHETIC CONJUGATED ESTROGENS, B updates RSS · CI watch RSS